Indy Hematology Review
Avatar

Chronic Myelomonocytic Leukemia: Define, Diagnosis, Prognostications and Treatment

By Indy Hematology Review FEATURING Ayalew Tefferi
By Indy Hematology Review FEATURING Ayalew Tefferi
303 views
April 12, 2018
Comments 1
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Related Videos

Penn Medicine Abramson Cancer Center

2025 Breast Cancer Highlights from International Medical Meetings: 5…

Thu, Mar 6, 2025
Total Health

2025 West Oncology Conference

Sat, Feb 8, 2025
14:01

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

475 views
06:46

ASH 2023 Insights: "Guadecitabine in Higher-Risk MDS and CMML Under …

Insights from 2023 ASH Annual Meeting

S. Urrutia

63 views
07:49

A Case of CMML With Recurrent Skin Involvement

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Arslan Davulcu

13 views
10:38

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not Survi…

Insights from 2023 ASH Annual Meeting

D. Tremblay

37 views
11:20

SOHO 2021 Update on CMML Overview of the Most Recent Data

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

G. Montalban-Bravo

56 views
15:33

2020 SOHO Updates on Oral HMAs in MDS: Can FDA-Approved Decitabine/C…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

G. Garcia-Manero

165 views
10:43

MD Anderson Immune Checkpoint Based Approaches in AML & MDS: Which C…

Naval Daver

148 views
21:24

2020 Update on Atypical CML, CMML & CNL: Is There Clinical Benefit t…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Tyner

41 views
12:19

How to Calculate Risk in MDS Patients?

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Sekeres

93 views
22:02

TGF Beta Pathway Inhibition in MDS: Luspatercept Significantly Decre…

University of Miami's 2nd Biennial Miami Leukemia Symposium

A. Verma

115 views
18:24

In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylatin…

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

A. Mishra

189 views
14:59

In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylatin…

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

R. Komrokji

181 views
14:36

Frontline Therapies in MDS: Leveling Lower-risk MDS

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Sekeres

40 views
20:00

MDS/MPN Overlap Through Interactive Case Based Discussion: Overview …

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

A. Kuykendall

44 views
05:28

Frontline Therapies in MDS: Hampering Higher-risk MDS

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Sekeres

19 views
26:41

2019 ASH Review on MDS: Luspatercept Under FDA Review, Novel Oral HM…

Cleveland Clinic's 20th Annual ASH Review

H. Carraway

27 views
20:06

2020 Update on Splicing in MDS: How Can We Target Spliceosome-Mutant…

University of Miami's 2nd Biennial Miami Leukemia Symposium

T. Graubert

11 views
11:18

Relapse After Allo HSCT - Treatment Strategies and Overview of Relat…

Indy Hematology Review

R. Childs

130 views
07:01

2019 ASH Review of MDS: Clonal Hematopoiesis Increases Risk for Hema…

Cleveland Clinic's 20th Annual ASH Review

H. Carraway

22 views
19:25

MDS/MPN: Senectus Ipsa Est Morbus (Disease of Old Age)?

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

M. Deininger

78 views
AUTOPLAY